In an editorial accompanying the NEJM publication, Christie M. Ballantyne, MD, and Vijay Nambi, MD, Baylor College of Medicine, Houston, Texas, point out that although the AEGIS-II trial showed no clinically meaningful early benefit, the trend towards possible benefit suggests that increasing cholesterol efflux capacity and reverse cholesterol transport may still have potential as a longer-term strategy if medications that can be used over the long term are developed and tested in populations wi...